Biogen's Leqembi set for strong uptake based on Baird physician survey
selvanegra/iStock via Getty Images

Leqembi (lecanemab), Biogen's Alzheimer's drug that recently won full US FDA approval, is set to capture significant market share, according to a new survey.
Investment house Baird conducted a survey of 30 physicians focused on Alzheimer's in late July. Results showed that 20 of them have the infrastructure in place to begin the infusions now, while another eight said they would have it done within the next six months.

Using triangulation based on an estimate for each physician's number of patients with mild cognitive impairment or mild dementia, Baird said that 41% of these patients were interested in anti-amyloid treatment.



Baird projects that in five years, annual sales of Leqembi could top $9.8B.
The full FDA approval of Leqembi is significant for Biogen (NASDAQ:BIIB) and partner Eisai (OTCPK:ESALF) given that CMS has stated Alzheimer's drugs that have such approval will be covered by Medicare.


More on Biogen

Biogen And Alzheimer's Disease: Too Early To Celebrate
Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?
Seeking Alphaâs Quant Rating on Biogen